Costa Rica

Costa Rica

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.73 (0.59 - 0.87) 2019 Modelled IHME
0.72 (0.60 - 0.84) 2018 Modelled IHME
0.72 (0.59 - 0.84) 2017 Modelled IHME
0.72 (0.60 - 0.84) 2016 Modelled IHME
0.73 (0.60 - 0.85) 2015 Modelled IHME
0.74 (0.61 - 0.86) 2014 Modelled IHME
0.75 (0.62 - 0.88) 2013 Modelled IHME
0.77 (0.63 - 0.89) 2012 Modelled IHME
0.79 (0.65 - 0.92) 2011 Modelled IHME
0.81 (0.65 - 0.95) 2010 Modelled IHME
0.82 (0.66 - 0.96) 2009 Modelled IHME
0.84 (0.67 - 0.98) 2008 Modelled IHME
0.85 (0.67 - 1.01) 2007 Modelled IHME
0.87 (0.68 - 1.03) 2006 Modelled IHME
0.88 (0.68 - 1.05) 2005 Modelled IHME
0.89 (0.70 - 1.05) 2004 Modelled IHME
0.89 (0.71 - 1.06) 2003 Modelled IHME
0.9 (0.72 - 1.07) 2002 Modelled IHME
0.91 (0.73 - 1.08) 2001 Modelled IHME
0.91 (0.73 - 1.10) 2000 Modelled IHME
0.93 (0.74 - 1.12) 1999 Modelled IHME
0.94 (0.75 - 1.14) 1998 Modelled IHME
0.96 (0.76 - 1.16) 1997 Modelled IHME
0.97 (0.77 - 1.18) 1996 Modelled IHME
0.98 (0.77 - 1.18) 1995 Modelled IHME
0.98 (0.78 - 1.18) 1994 Modelled IHME
0.98 (0.78 - 1.18) 1993 Modelled IHME
0.99 (0.79 - 1.18) 1992 Modelled IHME
0.99 (0.79 - 1.18) 1991 Modelled IHME
0.99 (0.79 - 1.19) 1990 Modelled IHME
1.19 (0.13 - 9.99) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.02 (0.02 - 0.03) 2019 Modelled IHME
0.02 (0.02 - 0.03) 2018 Modelled IHME
0.03 (0.02 - 0.03) 2017 Modelled IHME
0.03 (0.02 - 0.04) 2016 Modelled IHME
0.03 (0.02 - 0.04) 2015 Modelled IHME
0.03 (0.02 - 0.05) 2014 Modelled IHME
0.04 (0.03 - 0.05) 2013 Modelled IHME
0.05 (0.03 - 0.07) 2012 Modelled IHME
0.06 (0.04 - 0.08) 2011 Modelled IHME
0.06 (0.04 - 0.09) 2010 Modelled IHME
0.07 (0.05 - 0.10) 2009 Modelled IHME
0.08 (0.05 - 0.11) 2008 Modelled IHME
0.08 (0.06 - 0.11) 2007 Modelled IHME
0.09 (0.06 - 0.12) 2006 Modelled IHME
0.09 (0.06 - 0.12) 2005 Modelled IHME
0.09 (0.06 - 0.12) 2004 Modelled IHME
0.09 (0.06 - 0.12) 2003 Modelled IHME
0.09 (0.06 - 0.12) 2002 Modelled IHME
0.09 (0.06 - 0.12) 2001 Modelled IHME
0.09 (0.06 - 0.12) 2000 Modelled IHME
0.13 (0.09 - 0.17) 1999 Modelled IHME
0.24 (0.17 - 0.31) 1998 Modelled IHME
0.36 (0.26 - 0.48) 1997 Modelled IHME
0.47 (0.34 - 0.62) 1996 Modelled IHME
0.52 (0.37 - 0.69) 1995 Modelled IHME
0.52 (0.37 - 0.70) 1994 Modelled IHME
0.52 (0.37 - 0.70) 1993 Modelled IHME
0.52 (0.37 - 0.71) 1992 Modelled IHME
0.52 (0.36 - 0.72) 1991 Modelled IHME
0.53 (0.36 - 0.73) 1990 Modelled IHME
0.17 (0.02 - 1.73) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
14 (10 - 20) 2019 Modelled IHME
14 (10 - 21) 2018 Modelled IHME
15 (10 - 21) 2017 Modelled IHME
15 (10 - 20) 2016 Modelled IHME
14 (10 - 20) 2015 Modelled IHME
14 (10 - 20) 2014 Modelled IHME
15 (10 - 20) 2013 Modelled IHME
15 (10 - 20) 2012 Modelled IHME
15 (11 - 21) 2011 Modelled IHME
15 (11 - 21) 2010 Modelled IHME
15 (11 - 21) 2009 Modelled IHME
16 (11 - 21) 2008 Modelled IHME
16 (12 - 22) 2007 Modelled IHME
16 (12 - 22) 2006 Modelled IHME
17 (12 - 22) 2005 Modelled IHME
17 (12 - 22) 2004 Modelled IHME
17 (12 - 23) 2003 Modelled IHME
17 (12 - 23) 2002 Modelled IHME
17 (12 - 23) 2001 Modelled IHME
17 (12 - 23) 2000 Modelled IHME
17 (12 - 23) 1999 Modelled IHME
17 (12 - 23) 1998 Modelled IHME
17 (12 - 23) 1997 Modelled IHME
17 (12 - 23) 1996 Modelled IHME
17 (12 - 23) 1995 Modelled IHME
17 (12 - 23) 1994 Modelled IHME
17 (12 - 23) 1993 Modelled IHME
17 (12 - 23) 1992 Modelled IHME
17 (12 - 23) 1991 Modelled IHME
17 (12 - 23) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
90 2018 Survey/reported WHO/UNICEF
87 2017 Survey/reported WHO/UNICEF
91 2016 Survey/reported WHO/UNICEF
90 2015 Survey/reported WHO/UNICEF
89 2014 Survey/reported WHO/UNICEF
90 2013 Survey/reported WHO/UNICEF
90 2012 Survey/reported WHO/UNICEF
88 2011 Survey/reported WHO/UNICEF
86 2010 Survey/reported WHO/UNICEF
87 2009 Survey/reported WHO/UNICEF
87 2008 Survey/reported WHO/UNICEF
88 2007 Survey/reported WHO/UNICEF
88 2006 Survey/reported WHO/UNICEF
89 2005 Survey/reported WHO/UNICEF
89 2004 Survey/reported WHO/UNICEF
86 2003 Survey/reported WHO/UNICEF
87 2002 Survey/reported WHO/UNICEF
87 2001 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
97 2017 Survey/reported WHO/UNICEF
97 2016 Survey/reported WHO/UNICEF
92 2015 Survey/reported WHO/UNICEF
91 2014 Survey/reported WHO/UNICEF
94 2013 Survey/reported WHO/UNICEF
91 2012 Survey/reported WHO/UNICEF
84 2011 Survey/reported WHO/UNICEF
89 2010 Survey/reported WHO/UNICEF
87 2009 Survey/reported WHO/UNICEF
89 2008 Survey/reported WHO/UNICEF
89 2007 Survey/reported WHO/UNICEF
88 2006 Survey/reported WHO/UNICEF
90 2005 Survey/reported WHO/UNICEF
89 2004 Survey/reported WHO/UNICEF
86 2003 Survey/reported WHO/UNICEF
94 2002 Survey/reported WHO/UNICEF
80 2001 Survey/reported WHO/UNICEF
89 2000 Survey/reported WHO/UNICEF
83 1999 Survey/reported WHO/UNICEF
86 1998 Survey/reported WHO/UNICEF
76 1997 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.28 (1.85 - 2.81) 2019 Modelled IHME
2.26 (1.85 - 2.76) 2018 Modelled IHME
2.23 (1.82 - 2.73) 2017 Modelled IHME
2.19 (1.79 - 2.67) 2016 Modelled IHME
2.15 (1.74 - 2.64) 2015 Modelled IHME
2.12 (1.72 - 2.60) 2014 Modelled IHME
2.1 (1.70 - 2.56) 2013 Modelled IHME
2.07 (1.67 - 2.53) 2012 Modelled IHME
2.05 (1.66 - 2.51) 2011 Modelled IHME
2.04 (1.64 - 2.49) 2010 Modelled IHME
2.02 (1.63 - 2.49) 2009 Modelled IHME
2.01 (1.62 - 2.47) 2008 Modelled IHME
2 (1.61 - 2.46) 2007 Modelled IHME
1.99 (1.61 - 2.47) 2006 Modelled IHME
1.98 (1.61 - 2.45) 2005 Modelled IHME
1.98 (1.60 - 2.45) 2004 Modelled IHME
1.98 (1.58 - 2.42) 2003 Modelled IHME
1.97 (1.58 - 2.41) 2002 Modelled IHME
1.97 (1.58 - 2.40) 2001 Modelled IHME
1.97 (1.57 - 2.41) 2000 Modelled IHME
1.96 (1.57 - 2.40) 1999 Modelled IHME
1.96 (1.57 - 2.38) 1998 Modelled IHME
1.95 (1.57 - 2.39) 1997 Modelled IHME
1.95 (1.57 - 2.39) 1996 Modelled IHME
1.94 (1.56 - 2.41) 1995 Modelled IHME
1.94 (1.56 - 2.40) 1994 Modelled IHME
1.93 (1.56 - 2.38) 1993 Modelled IHME
1.92 (1.56 - 2.36) 1992 Modelled IHME
1.92 (1.54 - 2.35) 1991 Modelled IHME
1.91 (1.53 - 2.35) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
37 (28 - 47) 2019 Modelled IHME
37 (28 - 46) 2018 Modelled IHME
37 (28 - 46) 2017 Modelled IHME
37 (28 - 46) 2016 Modelled IHME
37 (29 - 47) 2015 Modelled IHME
38 (29 - 47) 2014 Modelled IHME
38 (29 - 47) 2013 Modelled IHME
38 (29 - 47) 2012 Modelled IHME
37 (29 - 46) 2011 Modelled IHME
37 (28 - 47) 2010 Modelled IHME
38 (29 - 46) 2009 Modelled IHME
37 (28 - 46) 2008 Modelled IHME
37 (28 - 46) 2007 Modelled IHME
37 (28 - 45) 2006 Modelled IHME
37 (28 - 46) 2005 Modelled IHME
37 (28 - 45) 2004 Modelled IHME
37 (28 - 46) 2003 Modelled IHME
37 (28 - 46) 2002 Modelled IHME
37 (28 - 46) 2001 Modelled IHME
37 (28 - 46) 2000 Modelled IHME
37 (28 - 46) 1999 Modelled IHME
37 (28 - 46) 1998 Modelled IHME
37 (28 - 46) 1997 Modelled IHME
37 (28 - 46) 1996 Modelled IHME
37 (28 - 46) 1995 Modelled IHME
37 (28 - 46) 1994 Modelled IHME
37 (28 - 46) 1993 Modelled IHME
37 (28 - 46) 1992 Modelled IHME
37 (28 - 46) 1991 Modelled IHME
37 (28 - 46) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.73 (%)
2019
(0.59 - 0.87(%))
IHME
HCV (RNA/cAg+)
2.28 (%)
2019
(1.85 - 2.81(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
69
2019
(48 - 95)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
332
2019
(232 - 454)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.02 (%)
2019, latest modelled
(0.02 - 0.03(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
90 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines